BRPI1012560A2 - anticorpos anti-fcrh5 e imunoconjugados e métodos de uso - Google Patents
anticorpos anti-fcrh5 e imunoconjugados e métodos de usoInfo
- Publication number
- BRPI1012560A2 BRPI1012560A2 BRPI1012560A BRPI1012560A BRPI1012560A2 BR PI1012560 A2 BRPI1012560 A2 BR PI1012560A2 BR PI1012560 A BRPI1012560 A BR PI1012560A BR PI1012560 A BRPI1012560 A BR PI1012560A BR PI1012560 A2 BRPI1012560 A2 BR PI1012560A2
- Authority
- BR
- Brazil
- Prior art keywords
- fcrh5
- methods
- immunoconjugate antibodies
- immunoconjugate
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21175409P | 2009-04-01 | 2009-04-01 | |
| US16621409P | 2009-04-02 | 2009-04-02 | |
| PCT/US2010/029521 WO2010114940A1 (en) | 2009-04-01 | 2010-03-31 | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012560A2 true BRPI1012560A2 (pt) | 2016-07-26 |
Family
ID=42236394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012560A BRPI1012560A2 (pt) | 2009-04-01 | 2010-03-31 | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8362213B2 (https=) |
| EP (1) | EP2414395A1 (https=) |
| JP (2) | JP6099976B2 (https=) |
| KR (1) | KR20120003478A (https=) |
| CN (1) | CN102369218B (https=) |
| AR (1) | AR076030A1 (https=) |
| AU (1) | AU2010232682A1 (https=) |
| BR (1) | BRPI1012560A2 (https=) |
| CA (1) | CA2756988A1 (https=) |
| CL (1) | CL2011002418A1 (https=) |
| IL (1) | IL215404A0 (https=) |
| MX (1) | MX2011010265A (https=) |
| PE (1) | PE20120877A1 (https=) |
| RU (2) | RU2583270C2 (https=) |
| SG (1) | SG174930A1 (https=) |
| TW (1) | TW201039846A (https=) |
| WO (1) | WO2010114940A1 (https=) |
| ZA (1) | ZA201107128B (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011010265A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
| WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| US8962804B2 (en) * | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| KR102356286B1 (ko) * | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| KR102447350B1 (ko) * | 2013-02-08 | 2022-09-23 | 노파르티스 아게 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
| EP2980097A4 (en) | 2013-03-29 | 2017-03-08 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of erap1 |
| MY171854A (en) | 2013-03-29 | 2019-11-05 | Sumitomo Dainippon Pharma Co Ltd | Wt1 antigen peptide conjugate vaccine |
| AU2014299561B2 (en) * | 2013-06-24 | 2017-06-08 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| EA032231B1 (ru) | 2013-10-11 | 2019-04-30 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
| CA2927022C (en) | 2013-10-11 | 2018-08-21 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| KR20170066421A (ko) | 2014-09-12 | 2017-06-14 | 제넨테크, 인크. | 항-cll-1 항체 및 면역접합체 |
| EP3212668B1 (en) | 2014-10-31 | 2020-10-14 | AbbVie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| WO2016090337A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| CN108064246A (zh) * | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| TWI731861B (zh) * | 2015-06-16 | 2021-07-01 | 美商建南德克公司 | FcRH5之人源化及親和力成熟抗體及使用方法 |
| EP3310378B1 (en) | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| KR20180089497A (ko) * | 2015-12-04 | 2018-08-08 | 메모리얼 슬로안-케터링 캔서 센터 | Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법 |
| JPWO2017188346A1 (ja) * | 2016-04-27 | 2019-02-28 | 国立大学法人 東京大学 | マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法 |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| EP3549957A4 (en) | 2016-11-30 | 2020-08-05 | Sumitomo Dainippon Pharma Co., Ltd. | AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER |
| MX2019015057A (es) * | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| CN110869050B (zh) | 2017-07-28 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 双特异性抗体配制剂 |
| TWI799438B (zh) * | 2017-08-10 | 2023-04-21 | 日商住友製藥股份有限公司 | 半星芒體衍生物及此等之抗體藥物複合體 |
| ES2974288T3 (es) | 2017-08-10 | 2024-06-26 | Sumitomo Pharma Co Ltd | Conjugados de anticuerpo-fármaco que incluyen un derivado de hemiasterlina |
| US10766613B2 (en) * | 2017-11-28 | 2020-09-08 | Textron Innovations Inc. | System and method for rotorcraft-weight-on-wheels flight state transition control |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック， インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
| CN112292401A (zh) | 2018-03-06 | 2021-01-29 | 英凯尔生物科技有限责任公司 | 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020023106A1 (en) * | 2018-07-25 | 2020-01-30 | Northeastern University | Selectivity screening for antimicrobial compounds |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| US12178879B2 (en) | 2019-02-13 | 2024-12-31 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivative and antibody-drug conjugate thereof |
| US12312419B2 (en) | 2019-02-13 | 2025-05-27 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivative having cysteine residue |
| JP7560255B2 (ja) * | 2019-02-13 | 2024-10-02 | 住友ファーマ株式会社 | ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| EP3996816A1 (en) * | 2019-07-08 | 2022-05-18 | Imcare Biotech, LLC | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
| WO2021050217A1 (en) | 2019-09-11 | 2021-03-18 | Imcare Biotech, Llc. | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| WO2021127489A1 (en) | 2019-12-18 | 2021-06-24 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP2023545099A (ja) | 2020-10-08 | 2023-10-26 | アフィメド ゲーエムベーハー | 三重特異性バインダー |
| KR20230100732A (ko) | 2020-11-04 | 2023-07-05 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이성 항체의 피하 투여 |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| EP4330381A1 (en) | 2021-04-27 | 2024-03-06 | Novartis AG | Viral vector production system |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
| AU2022382368A1 (en) | 2021-11-03 | 2024-05-02 | Affimed Gmbh | Bispecific cd16a binders |
| TWI882313B (zh) * | 2022-04-13 | 2025-05-01 | 美商建南德克公司 | 治療性蛋白質之醫藥組成物及使用方法 |
| CA3247048A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| CN120112650A (zh) | 2022-10-26 | 2025-06-06 | 诺华股份有限公司 | 慢病毒配制品 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| CN116199772B (zh) * | 2022-11-16 | 2023-10-17 | 怡道生物科技(苏州)有限公司 | Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用 |
| TW202544034A (zh) | 2024-05-06 | 2025-11-16 | 美商榮都醫療公司 | 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體 |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| KR100332254B1 (ko) | 1993-10-01 | 2002-09-27 | 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 | 신규인펩티드유도체 |
| US7074897B2 (en) | 1997-06-16 | 2006-07-11 | Genentech, Inc. | Pro943 polypeptides |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| EP1235847B1 (en) * | 1999-11-29 | 2016-01-20 | The Trustees of Columbia University in the City of New York | ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA |
| US7105149B1 (en) | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
| US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| AU2002329540A1 (en) * | 2001-06-20 | 2003-01-02 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| EP1487877B1 (en) | 2001-09-18 | 2010-10-27 | Genentech, Inc. | Compositions and methods for the diagnosis of tumors |
| US7858330B2 (en) | 2001-10-19 | 2010-12-28 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US7888478B2 (en) | 2002-09-11 | 2011-02-15 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| EP1696963A2 (en) | 2003-12-24 | 2006-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| KR101270829B1 (ko) * | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| WO2006039238A2 (en) | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| US20080247944A1 (en) | 2005-01-12 | 2008-10-09 | Robert Graziano | Irta-2 Antibodies and Their Uses |
| NZ563370A (en) * | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| WO2008109533A2 (en) * | 2007-03-02 | 2008-09-12 | Medarex, Inc. | Human antibodies that bind multiple irta family proteins, and uses thereof |
| WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| MX2011010265A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
-
2010
- 2010-03-31 MX MX2011010265A patent/MX2011010265A/es active IP Right Grant
- 2010-03-31 JP JP2012503682A patent/JP6099976B2/ja not_active Expired - Fee Related
- 2010-03-31 EP EP10711526A patent/EP2414395A1/en not_active Ceased
- 2010-03-31 AU AU2010232682A patent/AU2010232682A1/en not_active Abandoned
- 2010-03-31 WO PCT/US2010/029521 patent/WO2010114940A1/en not_active Ceased
- 2010-03-31 PE PE2011001751A patent/PE20120877A1/es not_active Application Discontinuation
- 2010-03-31 CA CA2756988A patent/CA2756988A1/en not_active Abandoned
- 2010-03-31 CN CN201080014347.1A patent/CN102369218B/zh not_active Expired - Fee Related
- 2010-03-31 TW TW099109950A patent/TW201039846A/zh unknown
- 2010-03-31 KR KR1020117025849A patent/KR20120003478A/ko not_active Abandoned
- 2010-03-31 SG SG2011069895A patent/SG174930A1/en unknown
- 2010-03-31 BR BRPI1012560A patent/BRPI1012560A2/pt not_active IP Right Cessation
- 2010-03-31 AR ARP100101080A patent/AR076030A1/es not_active Application Discontinuation
- 2010-03-31 RU RU2011144119/10A patent/RU2583270C2/ru not_active IP Right Cessation
- 2010-03-31 RU RU2016110891A patent/RU2016110891A/ru not_active Application Discontinuation
- 2010-03-31 US US12/751,791 patent/US8362213B2/en not_active Expired - Fee Related
-
2011
- 2011-09-27 IL IL215404A patent/IL215404A0/en unknown
- 2011-09-29 ZA ZA2011/07128A patent/ZA201107128B/en unknown
- 2011-09-30 CL CL2011002418A patent/CL2011002418A1/es unknown
-
2012
- 2012-11-09 US US13/673,565 patent/US9017951B2/en not_active Expired - Fee Related
-
2015
- 2015-08-27 JP JP2015168182A patent/JP2016028052A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102369218A (zh) | 2012-03-07 |
| JP2012522513A (ja) | 2012-09-27 |
| TW201039846A (en) | 2010-11-16 |
| MX2011010265A (es) | 2011-10-11 |
| CL2011002418A1 (es) | 2012-03-16 |
| JP6099976B2 (ja) | 2017-03-29 |
| ZA201107128B (en) | 2012-12-27 |
| PE20120877A1 (es) | 2012-08-06 |
| AU2010232682A1 (en) | 2011-11-10 |
| IL215404A0 (en) | 2011-12-29 |
| CN102369218B (zh) | 2014-07-16 |
| AR076030A1 (es) | 2011-05-11 |
| JP2016028052A (ja) | 2016-02-25 |
| SG174930A1 (en) | 2011-11-28 |
| US8362213B2 (en) | 2013-01-29 |
| RU2583270C2 (ru) | 2016-05-10 |
| WO2010114940A1 (en) | 2010-10-07 |
| US9017951B2 (en) | 2015-04-28 |
| US20130089497A1 (en) | 2013-04-11 |
| CA2756988A1 (en) | 2010-10-07 |
| HK1166805A1 (en) | 2012-11-09 |
| US20110171125A1 (en) | 2011-07-14 |
| RU2016110891A (ru) | 2018-11-27 |
| KR20120003478A (ko) | 2012-01-10 |
| EP2414395A1 (en) | 2012-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012676A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| BRPI1012560A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| PT2247620T (pt) | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização | |
| PT2474557E (pt) | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização | |
| BRPI1014544A8 (pt) | anticorpos anti-il-17f e metodos de uso dos mesmos | |
| PL2990421T3 (pl) | Przeciwciała anty-ceacam1 oraz sposoby ich stosowania | |
| BRPI0813514A2 (pt) | anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso | |
| BR112014028366A2 (pt) | anticorpos anti-ly6e e imunoconjugados e métodos de uso | |
| PL2427212T3 (pl) | Przeciwciała anty cd-100 i sposoby ich zastosowania | |
| BRPI1011384A2 (pt) | pro-proteinas e seus metodos de uso | |
| BR112012018329A2 (pt) | agentes de coloração e métodos de uso destes | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
| PL2488551T3 (pl) | Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania | |
| BRPI1007175A2 (pt) | Polipeptídeos hidroxifenilpriruvato dioxigenase mutantes e métodos de uso | |
| PL2644194T3 (pl) | Kombinacje koniugatu przeciwciała anty-HER2-lek i docetakselu | |
| BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
| BRPI0821110A2 (pt) | Anticorpo anti nr-10 e uso do mesmo | |
| BRPI0922708A2 (pt) | peptídeos mini-hepcidina e métodos de uso do mesmo | |
| BR112013014321A2 (pt) | moduladores inovadores e métodos de uso | |
| BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
| CO7020870A2 (es) | Anticuerpos anti-htra1 y métodos de uso | |
| BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
| BRPI1005670A2 (pt) | composições adjuvantes e métodos de uso | |
| CR20130133A (es) | Composiciones de anticuerpo y mètodos de uso | |
| BR112014010774A2 (pt) | anticorpos anti-kdr e métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2508 DE 29-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |